Business Context and Reporting Period
Company: China Pharma Holdings, Inc. (CPHI)
Filing Type: Form 8-K (Current Report)
Date of Report: July 22, 2026
Principal Executive Offices: Haikou, Hainan Province, China
Reporting Period: The filing reports on a material definitive agreement entered into on July 22, 2026.
Key Financial Metrics
This filing details a capital raise rather than operational financial performance. Key transaction metrics include:
- Transaction Type: Registered direct offering of common stock.
- Shares Issued: 2,500,000 shares.
- Purchase Price: $2.00 per share.
- Gross Proceeds: $5,000,000 (before fees and expenses).
- Placement Agent Fee: 7.0% of aggregate proceeds.
- Expected Closing Date: On or around July 23, 2026.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report, not a periodic financial statement.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with an institutional accredited investor. Material terms include:
- Right of First Refusal: The Investor has the right to participate in up to 40% of subsequent financings for three months following the Closing Date, on the same terms and price.
- Lock-Up Restrictions: For 91 days following the Closing Date, the Company is restricted from entering into agreements to issue securities (Subsequent Placement) or effect Variable Rate Transactions, subject to certain exceptions.
- Placement Agent: FT Global Capital, Inc. acted as the exclusive placement agent and is entitled to a 7.0% commission on this offering and potentially on future financings with contacted investors within 18 months.
Guidance, Outlook, and Risks
Management Commentary: The Company announced the offering via a press release (Exhibit 99.1) to secure capital. The offering is being conducted pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276481).
Risks and Contingencies:
- Dilution: The issuance of 2,500,000 new shares will result in dilution to existing shareholders.
- Future Financing Constraints: The 91-day lock-up period limits the Company's ability to raise additional capital through other means during that window.
- Future Fees: The Company may incur additional placement agent fees for future financings with investors contacted by FT Global within 18 months.
Investor Verification Checklist
- Verify the exact closing date and final net proceeds after deducting the 7.0% placement fee and other offering expenses.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific exceptions to the 91-day lock-up period.
- Confirm the post-offering share count and the extent of dilution to existing shareholders.
- Assess the Company's immediate use of the $5,000,000 gross proceeds as detailed in the accompanying press release.